Kathleen N. Moore, MD
Data from phase I pooled expansion cohorts showed that mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, induced a solid response rate in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.
In this study, patients received 6 mg/kg mirvetuximab soravtansine every 3 weeks until disease progression, adverse event, or investigator or patient decision. Eligibility criteria for the 3 expansion cohorts were:
- platinum-resistant cohort—up to 5 prior lines of therapy with measurable disease;
- ovarian biopsy cohort—tumor can be biopsied, platinum sensitive or resistant, measurable or non-measurable disease, any number of prior lines of therapy;
- corticosteroid eye drop cohort—recurrent disease, regardless of platinum sensitivity, measurable or non-measurable disease, and 3 to 4 prior lines of therapy.
Patients had a median of 3 prior lines of therapy, and 85% of patients in the pooled population had platinum-resistant disease. All patients had received prior treatment with platinum compounds and taxanes, more than half had received bevacizumab (Avastin), and 22% had received a PARP inhibitor. In the pooled population, folate receptor alpha expression was low in 20% of patients, medium in 26%, and high in 54%.
“Whether or not it can be moved into platinum-sensitive or front-line populations remains to be seen,” she said.
Moore KN, Matulonis UA, O’Malley DM, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts. J Clin Oncol. 35, 2017 (suppl; abstr 5547).
... to read the full story